- Investor's Business Daily•9 hours ago
The FDA's track record for oncology "hits" bodes well for Merck's Keytruda plus chemo combo, Leerink says.
- Financial Times•17 hours ago
Anglo-Swedish drugmaker AstraZeneca is expanding its widely watched trials for durvalumab, a potential breakthrough treatment for several forms of cancer. The drug is among a group of therapies designed ...
- Barrons.com•7 days ago
As my colleague Johanna Bennett noted, comments made by President-elect Donald Trump today about the high prices of drugs, as well as the fact that so many are manufactured outside the U.S. has helped sink biotech and pharmaceutical stocks alike.
AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,500.00 x 6100|
|Ask||4,660.00 x 13000|
|Day's Range||4,529.00 - 4,688.01|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||23.25|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|